<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460525</url>
  </required_header>
  <id_info>
    <org_study_id>07-0003</org_study_id>
    <secondary_id>U01AI065683</secondary_id>
    <secondary_id>2U01AI065683-06</secondary_id>
    <secondary_id>Malaria-056 (110060)</secondary_id>
    <secondary_id>HSRRB # A-14262</secondary_id>
    <nct_id>NCT00460525</nct_id>
  </id_info>
  <brief_title>Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali</brief_title>
  <official_title>Randomized, Controlled Phase II Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, Baltimore County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malaria is a disease that affects many people in Africa. Malaria is caused by germs spread by
      mosquito bites. The purpose of this study is to compare the number of children who get
      malaria after receiving an experimental malaria vaccine (FMP2.1/AS02A) to the number of
      children who get malaria after receiving a vaccine for rabies (an approved vaccine that does
      not prevent malaria). The children will be assigned to one of the vaccine groups by chance.
      Participants and doctors will not know which vaccine was given. Study participants will
      include 400 children, ages 1-6 years, living in Bandiagara, Mali. Children will receive 3
      vaccine doses, by injection, to their upper arm. Study procedures will include physical exams
      and several blood samples. Participants will be involved in the study for 26 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, phase II clinical trial to evaluate the efficacy, safety
      and immunogenicity of the apical membrane antigen-1 of Plasmodium (P.) falciparum (AMA-1)
      malaria vaccine FMP2.1/AS02A using rabies vaccine as a control in healthy children 1-6 years
      old in Bandiagara, Mali. This study is linked to DMID protocol 05-0146, which is a phase I
      dose escalation trial at the same site in the same population. In this study, 400 subjects
      will be randomized in a 1:1 ratio to receive either 50 micrograms of FMP2.1 in 0.5 mL AS02A
      or rabies vaccine. Immunizations will be given on days 0, 30 and 60. Solicited adverse events
      will be recorded on the days of immunization and at 1, 2, 3 and 7 days after each
      immunization. Unsolicited adverse events will be recorded for 30 days after each
      immunization. Passive case detection will be used to capture clinical malaria episodes and
      adverse events including serious adverse events, and will occur by continuous availability of
      clinical care in a population with high utilization of this care. Active surveillance will be
      used to capture malaria infections and adverse events including serious adverse events. For
      active case detection, following the third dose, participants will be followed monthly for 6
      months and then at 12, 18 and 24 months after randomization, for clinical assessment, malaria
      smear and hemoglobin. Routine monthly malaria smears will not be read immediately unless
      symptoms are present. Children will be followed for 2 years after the first immunization.
      Sera will be collected for anti-FMP2.1 antibody titers on the days of immunization and 1, 3,
      6, 8, 12, 18 and 24 months after the first immunization. Peripheral blood mononuclear cells
      (PBMCs) will be collected on the days of immunization, 30 days after the third immunization
      and 8, 12, 18 and 24 months after the first immunization. The study Final Report will be
      based on data collected up to 6 months after the assigned date of the third immunization. A
      supplemental report will include data from the entire 24-month observation period. Primary
      study objectives are to: determine the efficacy of FMP2.1/AS02A in children aged 1-6 years
      against first clinical malaria episodes (axillary temperature of greater than or equal to
      37.5 degrees Celsius and parasitemia of greater than or equal to 2500/mm^3) occurring between
      randomization and 6 months after the assigned date of the third immunization; and assess the
      safety of the vaccine in children aged 1-6 years. Secondary study objectives are to: describe
      the dynamics of anti-AMA-1 antibody responses in recipients of the malaria vaccine compared
      to natural responses in the control group; determine whether serum anti-AMA-1 IgG titer by
      enzyme linked immunosorbent assay (ELISA) 1 month after the third immunization correlates
      with protection against clinical malaria episode; measure allele-specific efficacy against
      parasites with AMA-1 genotypes homologous to and heterologous to the 3D7 clone of P.
      falciparum; determine vaccine efficacy against clinical malaria episodes occurring between
      randomization and 6 months after the assigned date of the third immunization; and if efficacy
      is observed based on the primary endpoint, to determine vaccine efficacy against first
      clinical malaria episode and all clinical episodes (using increasing parasitemia thresholds)
      occurring during 2 years after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination</measure>
    <time_frame>0-7 days after first vaccination</time_frame>
    <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after each vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Second Vaccination.</measure>
    <time_frame>0-7 days after the second vaccination</time_frame>
    <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Third Vaccination.</measure>
    <time_frame>0-7 days after the third vaccination</time_frame>
    <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the First Vaccination</measure>
    <time_frame>Day 0-29 after first vaccination</time_frame>
    <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Second Vaccination</measure>
    <time_frame>Day 0-29 after second vaccination</time_frame>
    <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Third Vaccination</measure>
    <time_frame>Day 0-29 after third vaccination</time_frame>
    <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First Clinical Malaria Episode With Significant Parasitemia (2500/mm^3) and Temperature of Greater Than or Equal to 37.5 Degrees C.</measure>
    <time_frame>Occurring between randomization and 6 months after the assigned date of the 3rd immunization.</time_frame>
    <description>Time to first clinical malaria episode is displayed in a life table format to display the number of subjects at risk, the number with first clinical episode and the number censored at each time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events</measure>
    <time_frame>24 months after initial vaccination</time_frame>
    <description>A serious adverse event was defined as any untoward medical occurrence that results in death, is life threatening, results in persistent or significant disability/incapacity, requires in-patient hospitalization or prolongation of existing hospitalization or is a congenital anomaly/birth defect in the offspring of a study subject. In addition, important medical events that may jeopardize the participant or may require intervention to prevent one of the other outcomes listed above was considered serious.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence Density of Clinical Malaria Episode</measure>
    <time_frame>Between randomization and 6 months after 3rd immunization.</time_frame>
    <description>Clinical malaria episode was defined by significant parasitemia (2500/mm^3) and temperature of greater than or equal to 37.5 degrees C. Event rate was determined by dividing the number of episodes (150 for the Rabies group and 121 for the FMP2.1/ASO2A group) by the number of Person Years at Risk (PYAR) (126.341 for Rabies group and 127.411 for the FMP2.1/ASO2A group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Clinical Malaria Episode With Parasites With AMA-1 Genotype Homologous to the 3D7 Strain of P. Falciparum With Respect to Entire AMA-1 Sequence and With Respect to Key Amino Acid Residues.</measure>
    <time_frame>Occurring between randomization and 6 months after the assigned date of the 3rd immunization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by Enzyme Linked ImmunoSorbent Assay (ELISA) at Day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 0 prior to the first vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 30.</measure>
    <time_frame>Day 30 after initial vaccination</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 30, prior to the second vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 60.</measure>
    <time_frame>Day 60 after initial vaccination</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 60, prior to the third vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 90.</measure>
    <time_frame>Day 90 after initial vaccination</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 150.</measure>
    <time_frame>Day 150 after initial vaccination</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 240.</measure>
    <time_frame>Day 240 after initial vaccination</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 240.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 364</measure>
    <time_frame>Day 364 after initial vaccination</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 364.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 547</measure>
    <time_frame>Day 547 after initial vaccination</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 547.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 730</measure>
    <time_frame>Day 730 after initial vaccination</time_frame>
    <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 730.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>Rabies Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMP2.1/AS02A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMP2.1/AS02A</intervention_name>
    <description>3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).</description>
    <arm_group_label>FMP2.1/AS02A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies Vaccine</intervention_name>
    <description>White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.</description>
    <arm_group_label>Rabies Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 1-6 years inclusive at the time of screening

          -  Residing in Bandiagara town

          -  Appear to be in generally good health based on clinical and laboratory investigation

          -  Separate written informed consent obtained from the parent/guardian before screening
             and study start, respectively

          -  Available to participate in follow-up for the duration of study (26 months)

        Exclusion Criteria:

          -  Previous vaccination with an investigational vaccine or a rabies vaccine

          -  Use of an investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 30 days preceding the first study immunization, or planned use up to
             30 days after the third immunization

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first immunization. This
             exclusion includes any dose level of oral steroids or inhaled steroids, but not
             topical steroids.

          -  Confirmed or suspected immunosuppressive or immunodeficient condition, including human
             immunodeficiency virus (HIV) infection

          -  Confirmed or suspected autoimmune disease

          -  History of allergic reactions or anaphylaxis to immunizations or to any vaccine
             component

          -  History of serious allergic reactions to any substance, requiring hospitalization or
             emergent medical care

          -  History of allergy to tetracycline, doxycycline, nickel, Imidazole, eggs, neomycin,
             chlortetracycline or amphotericin B

          -  History of splenectomy

          -  Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than the
             upper limit of normal of the testing laboratory = 49.6 U/L)

          -  Laboratory evidence of renal disease (serum or plasma creatinine greater than 62 micro
             mol/L), or more than trace protein or blood on urine dipstick testing)

          -  Laboratory evidence of hematologic disease (absolute leukocyte count &lt;5,300/mm^3 or
             &gt;15,300/mm^3, absolute lymphocyte count &lt;2,300 mm^3, platelet count &lt;133,000/mm^3, or
             hemoglobin &lt;9.0 g/dL)

          -  Hepatitis B surface antigen positive

          -  Chronic skin condition that could interfere with vaccine site reactogenicity
             assessment

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first study immunization or planned administration during the study
             period

          -  Simultaneous participation in any other interventional clinical trial

          -  Acute or chronic pulmonary, cardiovascular, hepatic (including hepatomegaly), renal or
             neurological condition, severe malnutrition, or any other clinical findings that in
             the opinion of the PI may increase the risk of participating in the study

          -  Other condition that in the opinion of the Principal Investigator (PI) would
             jeopardize the safety or rights of a participant in the trial or would render the
             participant unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahamadou A Thera, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bamako</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bamako, Malaria Research and Training Center</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mali</country>
  </location_countries>
  <results_reference>
    <citation>Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, Fileta BB, Kitov S, Kolodny N, Heppner DG, Haynes JD, Lanar DE. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun. 2002 Jun;70(6):3101-10.</citation>
    <PMID>12011004</PMID>
  </results_reference>
  <results_reference>
    <citation>Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 2007 May 22;25(21):4203-12. Epub 2007 Mar 26.</citation>
    <PMID>17442466</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <results_first_submitted>July 2, 2010</results_first_submitted>
  <results_first_submitted_qc>August 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2010</results_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria, Mali, children, Plasmodium falciparum, vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the population of healthy children aged 1-6 years residing in the town of Bandiagara.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rabies Vaccine</title>
          <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
        </group>
        <group group_id="P2">
          <title>FMP2.1/AS02A</title>
          <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rabies Vaccine</title>
          <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
        </group>
        <group group_id="B2">
          <title>FMP2.1/AS02A</title>
          <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="199"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="1.5"/>
                    <measurement group_id="B2" value="3.4" spread="1.6"/>
                    <measurement group_id="B3" value="3.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mali</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination</title>
        <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after each vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
        <time_frame>0-7 days after first vaccination</time_frame>
        <population>All subjects receiving the vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination</title>
          <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after each vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
          <population>All subjects receiving the vaccination are included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/Fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Limitation of Arm Motion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of Arm Motion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Second Vaccination.</title>
        <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
        <time_frame>0-7 days after the second vaccination</time_frame>
        <population>All subjects receiving the vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Second Vaccination.</title>
          <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
          <population>All subjects receiving the vaccination are included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/Fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Limitation of Arm Motion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of Arm Motion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Third Vaccination.</title>
        <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
        <time_frame>0-7 days after the third vaccination</time_frame>
        <population>All subjects receiving the vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Third Vaccination.</title>
          <description>Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after vaccination. &quot;Reported Limitation of Arm Motion&quot; refers to the parents' report of the symptom while &quot;Limitation of Arm Motion&quot; refers to the clinicians' assessment of the symptom, collected separately.</description>
          <population>All subjects receiving the vaccination are included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/Fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Limitation of Arm Motion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of Arm Motion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the First Vaccination</title>
        <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
        <time_frame>Day 0-29 after first vaccination</time_frame>
        <population>All subjects receiving the vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the First Vaccination</title>
          <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
          <population>All subjects receiving the vaccination are included.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and labyrinth disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders, administrative site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, poisoning, and procedural complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive system and breast disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Density of Clinical Malaria Episode</title>
        <description>Clinical malaria episode was defined by significant parasitemia (2500/mm^3) and temperature of greater than or equal to 37.5 degrees C. Event rate was determined by dividing the number of episodes (150 for the Rabies group and 121 for the FMP2.1/ASO2A group) by the number of Person Years at Risk (PYAR) (126.341 for Rabies group and 127.411 for the FMP2.1/ASO2A group).</description>
        <time_frame>Between randomization and 6 months after 3rd immunization.</time_frame>
        <population>Analyses are ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Density of Clinical Malaria Episode</title>
          <description>Clinical malaria episode was defined by significant parasitemia (2500/mm^3) and temperature of greater than or equal to 37.5 degrees C. Event rate was determined by dividing the number of episodes (150 for the Rabies group and 121 for the FMP2.1/ASO2A group) by the number of Person Years at Risk (PYAR) (126.341 for Rabies group and 127.411 for the FMP2.1/ASO2A group).</description>
          <population>Analyses are ITT.</population>
          <units>Events Per PYAR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.187263"/>
                    <measurement group_id="O2" value="0.949683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Incidence density, defined as number of clinical malaria episodes per PYAR, was compared using Poisson regression. The null hypothesis of no vaccine efficacy was tested. The point and interval estimates for vaccine efficacy were obtained by transforming those for treatment effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>The a priori threshold for statistical significance was set at 0.05.</p_value_desc>
            <method>Poisson regression</method>
            <method_desc>No adjustments</method_desc>
            <param_type>Vaccine Efficacy, VE=1-RR=1-exp(ß)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
            <estimate_desc>Vaccine efficacy (VE) was defined as one minus the relative risk (RR), which was estimated by exponentiating the treatment parameter (ß) from the Poisson model fit.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Clinical Malaria Episode With Parasites With AMA-1 Genotype Homologous to the 3D7 Strain of P. Falciparum With Respect to Entire AMA-1 Sequence and With Respect to Key Amino Acid Residues.</title>
        <time_frame>Occurring between randomization and 6 months after the assigned date of the 3rd immunization.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by Enzyme Linked ImmunoSorbent Assay (ELISA) at Day 0</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 0 prior to the first vaccination.</description>
        <time_frame>Day 0</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by Enzyme Linked ImmunoSorbent Assay (ELISA) at Day 0</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 0 prior to the first vaccination.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.4" lower_limit="298.0" upper_limit="621.4"/>
                    <measurement group_id="O2" value="393.1" lower_limit="273.2" upper_limit="565.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 30.</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 30, prior to the second vaccination.</description>
        <time_frame>Day 30 after initial vaccination</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 30.</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 30, prior to the second vaccination.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.7" lower_limit="275.8" upper_limit="591.0"/>
                    <measurement group_id="O2" value="21248.7" lower_limit="17616.8" upper_limit="25629.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Second Vaccination</title>
        <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
        <time_frame>Day 0-29 after second vaccination</time_frame>
        <population>All subjects receiving the vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Second Vaccination</title>
          <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
          <population>All subjects receiving the vaccination are included.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and labyrinth disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders, administrative site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, poisoning, and procedural complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive system and breast disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Third Vaccination</title>
        <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
        <time_frame>Day 0-29 after third vaccination</time_frame>
        <population>All subjects receiving the vaccination are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Third Vaccination</title>
          <description>Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.</description>
          <population>All subjects receiving the vaccination are included.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and labyrinth disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders, administrative site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, poisoning, and procedural complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive system and breast disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to First Clinical Malaria Episode With Significant Parasitemia (2500/mm^3) and Temperature of Greater Than or Equal to 37.5 Degrees C.</title>
        <description>Time to first clinical malaria episode is displayed in a life table format to display the number of subjects at risk, the number with first clinical episode and the number censored at each time point.</description>
        <time_frame>Occurring between randomization and 6 months after the assigned date of the 3rd immunization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Clinical Malaria Episode With Significant Parasitemia (2500/mm^3) and Temperature of Greater Than or Equal to 37.5 Degrees C.</title>
          <description>Time to first clinical malaria episode is displayed in a life table format to display the number of subjects at risk, the number with first clinical episode and the number censored at each time point.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 0 - 30, Number at Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 0 - 30, Number with First Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 0 -30, Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 31 - 60, Number at Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 31 - 60, Number with First Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 31 - 60, Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 61 - 90 Number at Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 61 - 90, Number with First Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 61 - 90, Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 91 - 120, Number at Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 91 - 120, Number with First Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 91 - 120, Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 121 - 150, Number at Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 121 - 150, Number with First Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 121 - 150, Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 151 - 180, Number at Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 151 - 180, Number with First Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 151 - 180, Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 181 - 210, Number at Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 181 - 210, Number with First Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 181 - 210, Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 211 - 240, Number at Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 211 - 240, Number with First Episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 211 - 240, Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to first clinical malaria episode with significant parasitemia (2500/mm^3) and temperature of greater than or equal to 37.5 degrees C was analyzed by fitting a Cox Proportional Hazards model. The null hypothesis of no vaccine efficacy was tested by the stratified log-rank test (score test). The point and interval estimates for vaccine efficacy were obtained by transforming those for treatment effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <p_value_desc>The a priori threshold for statistical significance was set at 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>No adjustments were made.</method_desc>
            <param_type>Vaccine Efficacy, VE=1-RR=1-exp(ß)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
            <estimate_desc>Vaccine efficacy (VE) was defined as one minus the relative risk (RR), which was estimated by exponentiating the treatment parameter (ß) from the Cox model fit.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Serious Adverse Events</title>
        <description>A serious adverse event was defined as any untoward medical occurrence that results in death, is life threatening, results in persistent or significant disability/incapacity, requires in-patient hospitalization or prolongation of existing hospitalization or is a congenital anomaly/birth defect in the offspring of a study subject. In addition, important medical events that may jeopardize the participant or may require intervention to prevent one of the other outcomes listed above was considered serious.</description>
        <time_frame>24 months after initial vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events</title>
          <description>A serious adverse event was defined as any untoward medical occurrence that results in death, is life threatening, results in persistent or significant disability/incapacity, requires in-patient hospitalization or prolongation of existing hospitalization or is a congenital anomaly/birth defect in the offspring of a study subject. In addition, important medical events that may jeopardize the participant or may require intervention to prevent one of the other outcomes listed above was considered serious.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 60.</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 60, prior to the third vaccination.</description>
        <time_frame>Day 60 after initial vaccination</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 60.</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 60, prior to the third vaccination.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512.2" lower_limit="350.1" upper_limit="749.3"/>
                    <measurement group_id="O2" value="98199.0" lower_limit="86574.6" upper_limit="111384.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 90.</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 90.</description>
        <time_frame>Day 90 after initial vaccination</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 90.</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 90.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="781.8" lower_limit="524.8" upper_limit="1164.5"/>
                    <measurement group_id="O2" value="188449.1" lower_limit="165625.5" upper_limit="214417.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 150.</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 150.</description>
        <time_frame>Day 150 after initial vaccination</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 150.</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 150.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1202.9" lower_limit="813.3" upper_limit="1779.0"/>
                    <measurement group_id="O2" value="100746.5" lower_limit="85163.0" upper_limit="119181.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 240.</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 240.</description>
        <time_frame>Day 240 after initial vaccination</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 240.</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 240.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774.6" lower_limit="525.5" upper_limit="1141.8"/>
                    <measurement group_id="O2" value="65031.7" lower_limit="54999.2" upper_limit="76894.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 364</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 364.</description>
        <time_frame>Day 364 after initial vaccination</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 364</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 364.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505.0" lower_limit="353.9" upper_limit="720.5"/>
                    <measurement group_id="O2" value="42596.8" lower_limit="36549.9" upper_limit="49644.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 547</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 547.</description>
        <time_frame>Day 547 after initial vaccination</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 547</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 547.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1589.3" lower_limit="1075.0" upper_limit="2349.7"/>
                    <measurement group_id="O2" value="81205.1" lower_limit="66166.2" upper_limit="99662.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 730</title>
        <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 730.</description>
        <time_frame>Day 730 after initial vaccination</time_frame>
        <population>Analyses are ITT. No imputation techniques were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccine</title>
            <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
          </group>
          <group group_id="O2">
            <title>FMP2.1/AS02A</title>
            <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti-FMP2.1 Antibody Measured by ELISA at Day 730</title>
          <description>Titers of Anti-FMP2.1 antibody were determined by ELISA from sera collected at Day 730.</description>
          <population>Analyses are ITT. No imputation techniques were used.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="636.5" lower_limit="431.4" upper_limit="939.0"/>
                    <measurement group_id="O2" value="40605.3" lower_limit="33946.8" upper_limit="48569.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited adverse events were collected for 7 days after each immunization. Serious adverse events and unsolicited non-serious adverse events were collected for 24 months after initial vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rabies Vaccine</title>
          <description>Rabies vaccine administered on Days 0, 30, and 60.</description>
        </group>
        <group group_id="E2">
          <title>FMP2.1/AS02A</title>
          <description>50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.1)">Febrile Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.1)">Febrile convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.0)">Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.1)">Conjunctivitis</sub_title>
                <counts group_id="E1" events="71" subjects_affected="55" subjects_at_risk="201"/>
                <counts group_id="E2" events="61" subjects_affected="49" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.1)">Abdominal Pain</sub_title>
                <counts group_id="E1" events="57" subjects_affected="39" subjects_at_risk="201"/>
                <counts group_id="E2" events="74" subjects_affected="45" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.1)">Diarrhoea</sub_title>
                <counts group_id="E1" events="96" subjects_affected="64" subjects_at_risk="201"/>
                <counts group_id="E2" events="81" subjects_affected="48" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (11.0)">Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="65" subjects_affected="50" subjects_at_risk="201"/>
                <counts group_id="E2" events="120" subjects_affected="89" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="114" subjects_affected="92" subjects_at_risk="201"/>
                <counts group_id="E2" events="324" subjects_affected="180" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="167" subjects_affected="129" subjects_at_risk="201"/>
                <counts group_id="E2" events="438" subjects_affected="192" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="52" subjects_affected="46" subjects_at_risk="201"/>
                <counts group_id="E2" events="133" subjects_affected="104" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Bronchitis</sub_title>
                <counts group_id="E1" events="273" subjects_affected="126" subjects_at_risk="201"/>
                <counts group_id="E2" events="259" subjects_affected="121" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (11.0)">Ear infection</sub_title>
                <counts group_id="E1" events="65" subjects_affected="47" subjects_at_risk="201"/>
                <counts group_id="E2" events="55" subjects_affected="46" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (11.0)">Fungal skin infection</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="201"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.1)">Furuncle</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="201"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="201"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="59" subjects_affected="43" subjects_at_risk="201"/>
                <counts group_id="E2" events="54" subjects_affected="41" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (9.0)">Pharyngitis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="201"/>
                <counts group_id="E2" events="40" subjects_affected="33" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (9.0)">Pneumonia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="31" subjects_at_risk="201"/>
                <counts group_id="E2" events="42" subjects_affected="33" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (9.1)">Pyoderma</sub_title>
                <counts group_id="E1" events="71" subjects_affected="54" subjects_at_risk="201"/>
                <counts group_id="E2" events="89" subjects_affected="60" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="244" subjects_affected="127" subjects_at_risk="201"/>
                <counts group_id="E2" events="251" subjects_affected="123" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Salmonellosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (11.0)">Tinea capitis</sub_title>
                <counts group_id="E1" events="36" subjects_affected="30" subjects_at_risk="201"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (9.0)">Tonsillitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="201"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Trichomoniasis intestinal</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Varicella</sub_title>
                <counts group_id="E1" events="57" subjects_affected="57" subjects_at_risk="201"/>
                <counts group_id="E2" events="50" subjects_affected="49" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.1)">Wound</sub_title>
                <counts group_id="E1" events="51" subjects_affected="39" subjects_at_risk="201"/>
                <counts group_id="E2" events="49" subjects_affected="41" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.1)">Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Granulocyte count increased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="36" subjects_at_risk="201"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (11.0)">Haemoglobin increased</sub_title>
                <counts group_id="E1" events="145" subjects_affected="94" subjects_at_risk="201"/>
                <counts group_id="E2" events="143" subjects_affected="92" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="60" subjects_affected="47" subjects_at_risk="201"/>
                <counts group_id="E2" events="80" subjects_affected="59" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (11.0)">Red blood cell count increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="201"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="201"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (11.0)">Anorexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Anorexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="34" subjects_affected="25" subjects_at_risk="201"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="166" subjects_affected="109" subjects_at_risk="201"/>
                <counts group_id="E2" events="190" subjects_affected="104" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (9.0)">Rhinorrhoea</sub_title>
                <counts group_id="E1" events="46" subjects_affected="39" subjects_at_risk="201"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Rash papular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Skin lesion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mahamadou A. Thera, MD, MPH</name_or_title>
      <organization>Department of Epidemiology of Parasitic Diseases, University of Bamako</organization>
      <phone>223-222-8109</phone>
      <email>mthera@mrtcbko.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

